Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tisagenlecleucel -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tisagenlecleucel -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - dinutuximab beta, quantity: 4.5 mg/ml - solution - excipient ingredients: polysorbate 20; hydrochloric acid; sucrose; water for injections; histidine - qarziba is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

celltrion healthcare malaysia sdn. bhd. - infliximab -

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

celltrion healthcare malaysia sdn. bhd. - infliximab -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abciximab -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abciximab -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - rituximab -

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - rituximab 10 mg/ml (murine/human monoclonal antibody);  ;  ;   - concentrate for infusion - 10 mg/ml - active: rituximab 10 mg/ml (murine/human monoclonal antibody)       excipient: citric acid hydrochloric acid polysorbate 80 sodium chloride sodium citrate dihydrate water for injection - mabthera is indicated for the treatment of patients with: · cd20 positive, previously untreated low-grade or follicular, b-cell non-hodgkin's lymphoma in combination with chemotherapy. · cd20 positive, relapsed or chemoresistant low-grade or follicular, b-cell non-hodgkin's lymphoma. · cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. mabthera is indicated for maintenance treatment of patients with cd20 positive, low grade or follicular, b-cell non-hodgkin's lymphoma.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - abciximab 2 mg/ml - solution for injection - 2 mg/ml - active: abciximab 2 mg/ml excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - reopro is indicated as an adjunct to heparin and aspirin for: percutaneous coronary intervention: the prevention of ischaemic cardiac complications (death, myocardial infarction or need for urgent intervention) in patients during or following percutaneous coronary intervention (balloon angioplasty, atherectomy and stent placement).